[1]那文秀.奥沙利铂联合卡培他滨治疗晚期胃癌的疗效[J].医学信息,2020,33(06):144-145.[doi:10.3969/j.issn.1006-1959.2020.06.046]
　NA Wen-xiu.Efficacy of Oxaliplatin Combined with Capecitabine in the Treatment of Advanced Gastric Cancer[J].Medical Information,2020,33(06):144-145.[doi:10.3969/j.issn.1006-1959.2020.06.046]
点击复制

奥沙利铂联合卡培他滨治疗晚期胃癌的疗效()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年06期
页码:
144-145
栏目:
药物与临床
出版日期:
2020-03-15

文章信息/Info

Title:
Efficacy of Oxaliplatin Combined with Capecitabine in the Treatment of Advanced Gastric Cancer
文章编号:
1006-1959（2020）06-0144-02
作者:
那文秀
（瓦房店市中心医院肿瘤内科，辽宁 瓦房店 116300）
Author(s):
NA Wen-xiu
(Department of Oncology,Wafangdian Central Hospital,Wafangdian 116300,Liaoning,China)
关键词:
奥沙利铂; 卡培他滨; 晚期胃癌
Keywords:
Oxaliplatin; Capecitabine; Advanced gastric cancer
分类号:
R735.2
DOI:
10.3969/j.issn.1006-1959.2020.06.046
文献标志码:
A
摘要:
目的 观察奥沙利铂联合卡培他滨治疗晚期胃癌的效果。方法 选取2017年2月~2019年2月在瓦房店市中心医院肿瘤内科治疗的70例晚期胃癌患者为研究对象，采用随机数字表法分为对照组和观察组，各35例。对照组采用顺铂、亚叶酸钙联合5-氟尿嘧啶治疗，观察组采用奥沙利铂联合卡培他滨治疗，比较两组临床治疗总有效率、平均生存时间、生存质量评分及毒副反应发生情况。结果 观察组治疗总有效率为74.28%，高于对照组的57.14%，差异有统计学意义（P＜0.05）；观察组平均生存时间、生存质量评分均高于对照组，差异有统计学意义（P＜0.05）；观察组毒副反应发生率低于对照组，差异有统计学意义（P＜0.05）。结论 奥沙利铂联合卡培他滨治疗晚期胃癌效果确切，总有效率高，毒副反应少，有助于提高患者生存质量，延长生存时间。
Abstract:
Objective To observe the effect of oxaliplatin combined with capecitabine on advanced gastric cancer.Methods A total of 70 patients with advanced gastric cancer who were treated in the Department of Oncology of Wafangdian Central Hospital from February 2017 to February 2019 were selected as the research subjects. They were divided into the control group and the observation group by random number table method, with 35 cases in each group. The control group was treated with cisplatin, calcium folic acid combined with 5-fluorouracil, and the observation group was treated with oxaliplatin combined with capecitabine. The total effective rate, mean survival time, quality of life score, and side effects of clinical treatment were compared between the two groups.Results The total effective rate of treatment in the observation group was 74.28%, which was higher than 57.14% in the control group,the difference was statistically significant (P<0.05); The average survival time and quality of life scores in the observation group were higher than the control group,the difference was statistically significant (P<0.05); the incidence of toxic and side effects in the observation group was lower than that in the control group,the difference was statistically significant (P<0.05).Conclusion Oxaliplatin combined with capecitabine is effective in the treatment of advanced gastric cancer with high total effective rate and few toxic side effects, which can help improve the quality of life and prolong the survival time of patients.

参考文献/References:

[1]郑波,刘君,金莉.多西他赛对比奥沙利铂联合卡培他滨治疗晚期胃癌的临床观察[J].中国继续医学教育,2015,7(4):223-224.[2]顾术东,刘艳,刘凡,等.卡培他滨联合奥沙利铂或顺铂一线治疗晚期胃癌临床观察[J].中国医药导报,2013,10(26):96-98,101.[3]袁媛,于静,张昊,等.小剂量奥沙利铂联合卡培他滨治疗老年晚期胃癌患者疗效观察[J].山东医药,2015,50(52):52-53.[4]孙桂丽,王大鹏,任志红.替吉奥胶囊联合奥沙利铂治疗晚期胃癌的临床观察[J].实用癌症杂志,2014,27(6):600-601.[5]陆文,刘燕,邵丽华,等.奥沙利铂联合卡培他滨新辅助化疗治疗进展期胃癌的临床观察[J].实用医学杂志,2015,27(2):295-297.

相似文献/References:

[1]胡平华,黄 勤,李志华.含卡培他滨方案一线或后线治疗晚期乳腺癌的效果对比[J].医学信息,2018,31(22):142.[doi:10.3969/j.issn.1006-1959.2018.22.041]
　HU Ping-hua,HUANG Qin,LI Zhi-hua.Comparison of the Efficacy of Capecitabine Regimen in the Treatment of Advanced Breast Cancer with First-line or Posterior Line Therapy[J].Medical Information,2018,31(06):142.[doi:10.3969/j.issn.1006-1959.2018.22.041]
[2]郭 雪,石学军.替吉奥与卡培他滨同步放疗治疗复发性结直肠癌疗效与安全性的Meta分析[J].医学信息,2020,33(07):71.[doi:10.3969/j.issn.1006-1959.2020.07.021]
　GUO Xue,SHI Xue-jun.Meta-analysis of the Efficacy and Safety of Simultaneous Therapy of Tegafur and Capecitabine for Recurrent Colorectal Cancer[J].Medical Information,2020,33(06):71.[doi:10.3969/j.issn.1006-1959.2020.07.021]
[3]石 磊,孙新增,李宝山,等.Ⅱ、Ⅲ期结肠癌患者辅助化疗XELOX方案、FOLFOX方案的临床疗效、不良反应及生活质量对比[J].医学信息,2018,31(13):68.[doi:10.3969/j.issn.1006-1959.2018.13.020]
　SHI Lei,SUN Xin-zeng,LI Bao-shan,et al.Clinical Efficacy,Adverse Reactions and Quality of Life of Adjuvant Chemotherapy XELOX and FOLFOX in Patients with Stage II and III Colon Cancer[J].Medical Information,2018,31(06):68.[doi:10.3969/j.issn.1006-1959.2018.13.020]
[4]谢兴江,彭 强,侯松林,等.SOX和XELOX在进展期胃癌新辅助化疗中疗效及不良反应差异的Meta分析[J].医学信息,2021,34(07):67.[doi:10.3969/j.issn.1006-1959.2021.07.019]
　XIE Xing-jiang,PENG Qiang,HOU Song-lin,et al.Meta-analysis of the Differences in the Efficacy and Adverse Reactions of SOX and XELOX in Neoadjuvant Chemotherapy for Advanced Gastric Cancer[J].Medical Information,2021,34(06):67.[doi:10.3969/j.issn.1006-1959.2021.07.019]

更新日期/Last Update: 2020-03-15